Psoriasis Drug MIA

San Francisco - The anti-CD40 ligand monoclonal antibody IDEC-131, manufactured by IDEC Pharmaceuticals, was developed to treat autoimmune and inflammatory diseases, such as psoriasis. IDEC-131 targets the CD40 ligand on T cells and regulates the interaction between T cells and B cells.

Related Videos
Related Content

Improve Patient Outcomes With Better Language Access

March 28th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Recent Povorcitinib 2b Study Shows Improved Repigmentation

March 27th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Investigational LEO Pharma IL-22 Receptor Improves EASI Scores in AD

March 27th 2023

Risankizumab Efficacious in Clearing, Improving Plaque Psoriasis

March 27th 2023

Improve Patient Outcomes With Better Language Access

March 28th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Recent Povorcitinib 2b Study Shows Improved Repigmentation

March 27th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Investigational LEO Pharma IL-22 Receptor Improves EASI Scores in AD

March 27th 2023

Risankizumab Efficacious in Clearing, Improving Plaque Psoriasis

March 27th 2023

Improve Patient Outcomes With Better Language Access

March 28th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Recent Povorcitinib 2b Study Shows Improved Repigmentation

March 27th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Investigational LEO Pharma IL-22 Receptor Improves EASI Scores in AD

March 27th 2023

Risankizumab Efficacious in Clearing, Improving Plaque Psoriasis

March 27th 2023
© 2023 MJH Life Sciences

All rights reserved.